Next 10 |
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
2024-05-04 03:39:35 ET Summary Schwab U.S. Dividend Equity ETF is a popular choice for income-oriented investors, diversification and a defensive approach. SCHD offers exposure to dividend-paying firms with healthy balance sheets, offering investors resilience in turbulent times. ...
2024-05-02 16:09:01 ET More on Janux Therapeutics Janux Therapeutics: A Prime Target In Cancer Care's M&A Game Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux Therapeutics jump...
2024-05-02 12:40:21 ET More on Merck Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck Keytruda ...
2024-05-01 14:41:05 ET Summary Eli Lilly and Company's revenue for the first quarter of 2024 fell short of analysts' expectations, but the company exceeded forecasts on the bottom line. Sales of the company's obesity and diabetes drugs, particularly Mounjaro and Zepbound, saw sign...
2024-05-01 08:47:27 ET Merck ( NYSE: MRK ) has reported positive overall survival data from a late-stage trial of a combination therapy for advanced gastric or gastroesophageal junction (GEJ) cancer.... Read the full article on Seeking Alpha For further details see: ...
These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA ® (pembrolizum...
2024-04-29 10:20:44 ET More on Merck Merck pneumococcal shot shows superior immunogenicity in late-stage trial Merck pneumococcal vaccine outperforms PCV20 in Phase 3 trials Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) ...
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases Results build on the data supporting the clinical profile of V116 for adults Merck (NYSE: MRK), known as MSD outside of the United Stat...
2024-04-29 06:32:13 ET Summary iShares U.S. Tech Breakthrough Multisector ETF owns a diversified portfolio of U.S. large-cap stocks benefiting from breakthrough technologies. The Fund has generally outperformed the S&P 500 in bull markets but underperformed in bear markets sin...
News, Short Squeeze, Breakout and More Instantly...
ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrang...
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouragin...
These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA ® (pembrolizum...